Wisman GBA — Endo Lab

2024

Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.

Journal of translational medicine ·doi:10.1186/s12967-024-05311-7

BackgroundThe poor chemo-response and high DNA methylation of ovarian clear cell carcinoma (OCCC) have attracted extensive attentions. Recently, we revealed the mutational landscape of the human kinome and additional cancer-related genes an…

2018

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Oncogene ·doi:10.1038/s41388-018-0300-6

Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50…

2018

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-17-3060

Purpose: Advanced-stage ovarian clear cell carcinoma (OCCC) is unresponsive to conventional platinum-based chemotherapy. Frequent alterations in OCCC include deleterious mutations in the tumor suppressor ARID1A and activating mutations in t…